This study is looking at a new blood test called the Subtraction Normalized Expression of Phagocytes (SNEP) Assay. This test uses RNA sequencing to identify prostate cancer and how aggressive it might be. The goal is to see how well this non-invasive blood test can find hidden aggressive prostate cancer in men who are already on active surveillance (closely watching their cancer without immediate treatment). You might be able to join if you are a man between 40 and 80 years old with at least a 10-year life expectancy, are currently on active surveillance with only one previous low-grade prostate biopsy, and are scheduled for your first annual biopsy within 90 days of joining. The study aims to collect performance results on the assay's ability to identify aggressive disease, measured at 1 year. The current status of this study is unclear.

Study design

This is an observational study planning to enroll 2000 men. It is designed to assess the performance of a blood test for managing prostate cancer.

What's involved

You must be scheduled for your first annual biopsy under your active surveillance protocol within 90 days of enrollment. The study will collect performance results on the assay's ability to identify occult aggressive disease.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 1 year, indicating follow-up for at least that duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.